Insider Transactions in Q4 2024 at Biocryst Pharmaceuticals Inc (BCRX)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 20
2024
|
Jon P Stonehouse President & CEO |
BUY
Bona fide gift
|
Indirect |
20,000
+25.0%
|
-
|
|
Dec 20
2024
|
Jon P Stonehouse President & CEO |
SELL
Bona fide gift
|
Direct |
20,000
-1.38%
|
-
|
|
Dec 19
2024
|
Helen M. Thackray Chief R&D Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,096
-1.56%
|
$42,672
$7.39 P/Share
|
|
Dec 19
2024
|
Helen M. Thackray Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,950
+24.37%
|
-
|
|
Dec 19
2024
|
Charles K Gayer Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,461
-0.58%
|
$17,227
$7.39 P/Share
|
|
Dec 19
2024
|
Charles K Gayer Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,950
+22.82%
|
-
|
|
Dec 19
2024
|
Anthony Doyle Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,461
-0.65%
|
$17,227
$7.39 P/Share
|
|
Dec 19
2024
|
Anthony Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,700
+24.09%
|
-
|
|
Dec 19
2024
|
Alane P Barnes Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,461
-0.59%
|
$17,227
$7.39 P/Share
|
|
Dec 19
2024
|
Alane P Barnes Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,700
+22.52%
|
-
|
|
Dec 19
2024
|
Jon P Stonehouse President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,010
-0.96%
|
$98,070
$7.39 P/Share
|
|
Dec 19
2024
|
Jon P Stonehouse President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
362,100
+19.84%
|
-
|
|
Dec 14
2024
|
Charles K Gayer Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,251
-2.68%
|
$57,757
$7.53 P/Share
|
|
Dec 14
2024
|
Jon P Stonehouse President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
27,525
-2.44%
|
$192,675
$7.53 P/Share
|
|
Dec 14
2024
|
Alane P Barnes Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,613
-2.84%
|
$60,291
$7.53 P/Share
|
|
Dec 14
2024
|
Anthony Doyle Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,890
-2.95%
|
$55,230
$7.53 P/Share
|
|
Dec 14
2024
|
Helen M. Thackray Chief R&D Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,150
-2.63%
|
$50,050
$7.53 P/Share
|
|
Dec 13
2024
|
Nancy J Hutson Director |
SELL
Open market or private sale
|
Direct |
7,000
-7.48%
|
$49,000
$7.54 P/Share
|
|
Nov 29
2024
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
750
+0.98%
|
$5,250
$7.5 P/Share
|